Abivax

company in Paris, France

ISIN FR0012333284 LEI 969500D8TMNB184OJU95
Follow Abivax Weekly email: filings, results

Financials

Reported figures only · latest: fiscal 2025 EUR · IFRS
Net income −€336.1M −90.7% vs prior year
EPS, diluted −€4.83 −72.5% vs prior year
Operating cash flow −€161.1M −4.6% vs prior year
Operating income −€246.1M −42.2% vs prior year
Net income by fiscal year
−€60.7M
−€147.7M
−€176.2M
−€336.1M
FY22 FY23 FY24 FY25

Source: ESEF annual reports · latest filing

The long view

Fiscal years as reported · ESEF annual reports, IFRS
Revenue and net income4 fiscal years
−€400M−€300M−€200M−€100M€0FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−€336.1M
FY24−€176.2M
FY23−€147.7M
FY22−€60.7M
Free cash flowOperating cash flow minus capital expenditure
−€200M−€150M−€100M−€50M€0FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−€161.3M
FY24−€154.7M
FY23−€97.4M
FY22−€54.2M